Prothena Corp. (PRTA) Adds Sanjiv Patel to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors
May 20, 2021 4:05 PM EDTDUBLIN, Ireland, May 20, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ: PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Sanjiv K. Patel, MBBS, MA, MBA, to its Board of Directors.
Sanjiv is an experienced leader with significant industry experience that uniquely positions him to guide us as we look towards transitioning to a fully integrated research, development and commercial biotechnology company, commented Lars Ekman, MD, PhD, Prothenas Chairman. We welcome Sanjiv to our Board and look forward... More
